{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=No+Labels+%28Control%29", "query": { "intervention": "No Labels (Control)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 283, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=No+Labels+%28Control%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T06:08:26.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06473779", "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Asthma" ], "interventions": [ { "name": "Tezepelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Budesonide/formoterol", "type": "COMBINATION_PRODUCT" }, { "name": "Albuterol/budesonide (AIRSUPRA®)", "type": "COMBINATION_PRODUCT" }, { "name": "Mannitol", "type": "COMBINATION_PRODUCT" }, { "name": "Salbutamol", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 326, "start_date": "2024-09-30", "completion_date": "2027-06-25", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 8, "location_summary": "Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "Palmdale", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06473779" }, { "nct_id": "NCT01713946", "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex-associated Refractory Seizures" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antiepileptic drug (1 to 3 only)", "type": "DRUG" }, { "name": "open label RAD001 (only used for post-extension phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2013-04-29", "completion_date": "2017-10-25", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01713946" }, { "nct_id": "NCT03744871", "title": "Air Pollution: Strategies for Personalized Intervention to Reduce Exposure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Air Pollution" ], "interventions": [ { "name": "N95 Respirator", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-03-22", "completion_date": "2023-07-31", "has_results": false, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03744871" }, { "nct_id": "NCT06125951", "title": "Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dementia Moderate", "Dementia, Mild", "Alzheimer Disease" ], "interventions": [ { "name": "Xanamem", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actinogen Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 247, "start_date": "2024-04-12", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 19, "location_summary": "Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Delray Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06125951" }, { "nct_id": "NCT04572854", "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "C3G", "IC-MPGN", "Renal Transplant", "Complement 3 Glomerulopathy", "Complement 3 Glomerulopathy (C3G)", "Dense Deposit Disease (DDD)", "Membranoproliferative Glomerulonephritis", "Membranoproliferative Glomerulonephritis (MPGN)", "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)", "C3 Glomerulopathy", "C3 Glomerulonephritis", "Complement 3 Glomerulonephritis" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-09-07", "completion_date": "2026-01-20", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572854" }, { "nct_id": "NCT02338960", "title": "2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypoactive Sexual Desire Disorder" ], "interventions": [ { "name": "Bremelanotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palatin Technologies, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 714, "start_date": "2015-01", "completion_date": "2017-06-29", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02338960" }, { "nct_id": "NCT04861571", "title": "Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "NAFLD" ], "interventions": [ { "name": "Dietary intervention with very low calorie diet (VLCD)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Control Arm", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2023-10-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04861571" }, { "nct_id": "NCT01566630", "title": "Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pre-eclampsia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RLX030", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 3, "start_date": "2013-05", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 4, "location_summary": "Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01566630" }, { "nct_id": "NCT03496012", "title": "Efficacy and Safety of BIIB111 for the Treatment of Choroideremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Choroideremia" ], "interventions": [ { "name": "BIIB111", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 169, "start_date": "2017-12-11", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2023-12-07", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 8, "location_summary": "Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03496012" }, { "nct_id": "NCT03346057", "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Reversal of Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 16 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Rocuronium", "type": "DRUG" }, { "name": "Vecuronium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2017-12-20", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-09-05T06:08:26.312Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03346057" } ] }